Publications by authors named "Kuninori Iwayama"

Introduction: In pharmacotherapy for inflammatory bowel disease (IBD), good medication adherence is necessary to control the condition. However, some patients show poor adherence. Pharmacists need to provide appropriate medication guidance to improve medication adherence.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how autophagy impacts the inflammatory response triggered by lipopolysaccharide (LPS) in RAW264.7 cells, focusing on the MyD88/NF-kB signaling pathway.
  • Researchers used chloroquine (CQ) as an autophagy inhibitor and found it reduced levels of pro-inflammatory cytokines and influenced other inflammatory mediators in LPS-stimulated cells.
  • The findings suggest that CQ could be a potential therapeutic target for managing inflammatory diseases by regulating inflammatory responses.
View Article and Find Full Text PDF

Background/aim: Recent lung cancer treatments include an immune checkpoint inhibitor (ICI) pembrolizumab, platinum-based agents, plus an additional cytotoxic anticancer agent. Nutritional indices, such as the geriatric nutritional risk index (GNRI) and the prognostic nutritional index (PNI), are known to correlate with the prognosis of cancer chemotherapy. Several previous studies have investigated the relationship between PNI and treatment response in non-small cell lung cancer patients, reporting significantly increased OS and PFS in the high PNI group before treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Carbapenems, like meropenem (MEPM), are often used against ESBL-producing bacteria, and the study focuses on the effectiveness of cefmetazole (CMZ) for treating ESBL-EC bacteremia.
  • The research analyzed inpatients with ESBL-EC from 2018 to 2023 and compared their recovery times across four treatment groups: CMZ, MEPM, de-escalation to CMZ, and escalation to MEPM.
  • Findings indicated that while there was no significant difference in overall recovery time, CMZ showed a tendency for longer recovery compared to MEPM, particularly underscoring the importance of initial treatment choices.
View Article and Find Full Text PDF

Introduction: Sotorasib is a crucial therapeutic agent for patients with non-small cell lung cancer (NSCLC) harboring the KRAS p.G12C mutation. Despite its efficacy, the relationship between blood sotorasib concentrations and side effects remains largely unexplored.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to understand how blood levels of Osimertinib affect treatment continuation in patients with EGFR mutation-positive lung cancer.
  • It analyzed data from 56 patients and found that higher drug levels correlate with improved progression-free survival (PFS) but did not significantly impact overall treatment efficacy.
  • The research concluded that lower serum albumin levels were linked to shorter PFS, potentially influenced by factors like inflammation and liver function in cancer patients.
View Article and Find Full Text PDF

Background/aim: Interstitial lung disease (ILD) is a serious adverse event (AE) associated with the use of immune checkpoint inhibitors (ICIs). However, the risk factors for developing ICI-related ILD remain poorly understood. Therefore, this study investigated the effect of concomitant analgesics on developing ICI-related ILD using the Japanese Adverse Drug Event Report (JADER) database.

View Article and Find Full Text PDF

Background: It is well known that low-dose, long-term macrolide therapy is effective against chronic inflammatory airway diseases. Oxidative stress is considered to be a key pathogenesis factor in those diseases. However, the mechanism of action of low-dose, long-term macrolide therapy remains unclear.

View Article and Find Full Text PDF

Background: Clarithromycin (CAM), a representative macrolide antibiotic, has been used widely at low doses for long-term therapy of chronic inflammatory airway diseases. Anti-inflammatory effects of macrolide antibiotics were first discovered in clinical practice. Although oxidative stress is known as a key pathogenesis factor in chronic airway inflammatory diseases, the mechanism of action of low-dose, long-term CAM therapy remains unclear.

View Article and Find Full Text PDF

Drugs are sometimes covered with oblate or agar jelly. It is said that the medicinal effect of drugs covered with oblate is slow, but no studies have reported results confirming this. Therefore, we examined the dissolution behavior when the drug was covered with oblate or agar jelly.

View Article and Find Full Text PDF